Dermatology
Latest News
Neurofibromatosis: What Affects Quality of Life Most?
“To develop effective therapeutics, meaningful clinical outcomes that are tied with improvement in QoL for persons with NF1 must be clearly...
Feature
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal Intervention
OIG reports showed a spike in ustekinumab costs for patients in Medicare Part D. Experts said Inflation Reduction Act changes in Medicare drug...
Latest News
Support for Laser Treatment to Reduce NMSC Risk is Increasing
There is a “growing body of research that demonstrates we are improving the health of our patients’ skin with certain types of laser treatments,...
Latest News
Hidradenitis Suppurativa Risk Reduced After Patients Quit Smoking
“Smoking cessation and maintaining a smoke-free lifestyle may be important preventive measures against the development of HS,” study authors said...
Latest News
TYK2 Inhibitor Effective for Psoriasis in Phase 2 Study
At week 12, PASI 75 was achieved by 18%, 44%, 68%, and 67% of patients receiving zasocitinib at doses of 2 mg, 5 mg, 15 mg, and 30 mg,...
Latest News
Timing of iPLEDGE Updates Unclear
On November 30, 2023, the FDA informed isotretinoin manufacturers that they had 6 months to make five changes to the iPLEDGE REMS, addressing the...
From the Journals
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
GLP-1 RAs were associated with a decreased risk for all-cause mortality and major adverse cardiovascular events in patients with immune-mediated...
Feature
Do You Have Patients With JAKne — JAK Inhibitor–Associated Acne? Here’s What to Know
Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.
Opinion
A 62-year-old Black female presented with an epidermal inclusion cyst on her left upper back
The patient is awaiting cardiac transplant secondary to the underlying condition.
Latest News
Diagnosing, Treating Rashes In Patients on Immune Checkpoint Inhibitors
Cutaneous immune-related adverse events are the most frequently reported and most visible adverse effects of checkpoint inhibition.
Latest News
Second Treatment for Prurigo Nodularis Approved by FDA
Nemolizumab is currently under FDA review for treating atopic dermatitis in...